Cagrilintide dosing in published studies (not a recommendation)
3 regimens from 3 cited studies, 3 of them in humans. Each row states what the study gave, to whom, by what route, and links to the paper. Nothing on this page is a dose for you or anyone else.
This page reports what published studies found. It is not medical advice, no provider-patient relationship is created by reading it, and nothing here is a recommendation to use any compound. Talk with a licensed clinician about your own situation. Read the full disclaimer.
Regulatory status in the United States
Status reviewed September 16, 2026
FDA-approved drug
No. Cagrilintide is not an FDA-approved drug for any use.
503A compounding
Not on FDA's 503A lists. Not nominated for, or not currently on, FDA's list of bulk drug substances permitted for 503A compounding.
How it is obtained
Sold only as a research chemical labeled “not for human use.” No lawful prescription pathway exists for it today.
Cagrilintide is not an FDA-approved drug for any use. It is not on FDA's 503A bulk drug substances lists, and no lawful prescription pathway for a compounded version was identified at the review date. Products sold as "research use only" are not intended for human use and are not a lawful substitute for a prescription. This status comes from the site's regulatory review, not from the studies cited on this page.
Regimens the studies reported
Doses that cited studies administered to their participants. Reported as research, not recommendations.
Regimen as reported
Population
Route
Source
Cagrilintide alone at a dose of 2.4 mg, or semaglutide at a dose of 2.4 mg combined with cagrilintide at a dose of 2.4 mg, plus lifestyle interventions, over 68 weeksThe trial randomised participants 21:3:3:7 to cagrilintide-semaglutide, semaglutide alone, cagrilintide alone or placebo.
Adults without diabetes with a BMI of 30 or higher, or 27 or higher with at least one obesity-related complication (REDEFINE 1, n=3417)
Once-weekly cagrilintide-semaglutide (2.4 mg each) or placebo, along with lifestyle intervention, for 68 weeksPatients were assigned in a 3:1 ratio to cagrilintide-semaglutide or placebo.
Adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes (REDEFINE 2, n=1206)
Once weekly doses of cagrilintide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. for 2 weeks, given with semaglutide as separate injections or combined in a single injectionRegistration text describing planned administration; the listing does not report results.
People with overweight or obesity enrolled in a completed phase 1 pharmacokinetic study (n=40)
Each regimen is transcribed from the cited paper: the amount, the route and the schedule as the authors described them, and the population the paper enrolled. Amounts are not averaged, converted or extrapolated across studies, and a regimen given to rats or to two volunteers says nothing about any other group.
Rows marked as coming from a research digest were added automatically when the pipeline processed a new study; the profile rows were written by hand from the sources on the Cagrilintide profile. Both kinds carry the same citation requirement.
Frequently asked questions
What is cagrilintide?
Cagrilintide is a long-acting amylin analogue under investigation for weight management, developed as a once-weekly injection and also combined with the GLP-1 receptor agonist semaglutide under the name CagriSema (Lancet dose-finding trial, 2021; Cardiology in Review, 2023). Amylin itself is a hormone co-secreted with insulin that induces satiety and reduces body weight (Amylin review, 2024). Cagrilintide is not an FDA-approved drug.
What does the human evidence show for cagrilintide on its own?
The main published stand-alone evidence is a 26-week randomised phase 2 dose-finding trial in adults with overweight or obesity without diabetes. Mean percentage weight reductions were greater with every cagrilintide dose tested than with placebo, and greater with the highest cagrilintide dose than with once-daily liraglutide (Lancet dose-finding trial, 2021). REDEFINE 1 included a cagrilintide-alone arm of 302 participants, but the published abstract reports the weight outcome for the combination versus placebo rather than for that arm (REDEFINE 1, 2025).
How much weight loss was reported with CagriSema?
In REDEFINE 1, estimated mean percent change in body weight at week 68 was -20.4% with cagrilintide-semaglutide versus -3.0% with placebo in adults without diabetes (REDEFINE 1, 2025). In REDEFINE 2, in adults with type 2 diabetes, it was -13.7% versus -3.4% with placebo (REDEFINE 2, 2025). A network meta-analysis in type 2 diabetes ranked CagriSema highest for weight loss at -14.03 kg versus placebo (BMJ network meta-analysis, 2024), and a later analysis in adults without diabetes reported -17.32% versus placebo, behind retatrutide and tirzepatide (BMJ Medicine network meta-analysis, 2026).
How was cagrilintide given in the studies?
Trials used once-weekly subcutaneous administration with stepwise dose escalation before a maintenance period. REDEFINE 1 used cagrilintide alone at a dose of 2.4 mg, or semaglutide 2.4 mg with cagrilintide 2.4 mg, plus lifestyle interventions over 68 weeks (REDEFINE 1, 2025), and REDEFINE 2 used once-weekly cagrilintide-semaglutide (2.4 mg each) for 68 weeks in adults with type 2 diabetes (REDEFINE 2, 2025). A phase 1 pharmacokinetic study describes once-weekly cagrilintide gradually increased to 1.7 mg over 14 weeks and 2.4 mg subcutaneously for 2 weeks (NCT04940078).
What side effects were reported?
Gastrointestinal events dominate. In the phase 2 trial of cagrilintide alone, the most frequent adverse events were gastrointestinal disorders such as nausea, constipation and diarrhoea, plus administration-site reactions, with gastrointestinal events in 41%-63% of cagrilintide groups versus 32% on placebo (Lancet dose-finding trial, 2021). With the combination, gastrointestinal adverse events affected 79.6% versus 39.9% on placebo in REDEFINE 1 (REDEFINE 1, 2025) and 72.5% versus 34.4% in REDEFINE 2, mostly transient and mild or moderate (REDEFINE 2, 2025). A pooled analysis reported no increase in serious adverse events (CagriSema meta-analysis, 2026).
Does cagrilintide affect blood sugar?
In REDEFINE 2, 73.5% of patients receiving cagrilintide-semaglutide reached a glycated hemoglobin level of 6.5% or less versus 15.9% on placebo (REDEFINE 2, 2025). In REIMAGINE 1, both tested dose levels of cagrilintide-semaglutide lowered HbA1c significantly more than placebo at week 40 in adults with type 2 diabetes inadequately controlled with diet and exercise (REIMAGINE 1, 2026). A pooled analysis of CagriSema trials described glycemic outcomes as heterogeneous while lipid parameters improved versus placebo (CagriSema meta-analysis, 2026). The fetched sources do not isolate glycaemic effects of cagrilintide alone.
Where Cagrilintide is prescribed
Any amount a prescriber writes for is their decision, made for one patient. These programs list Cagrilintide on their own sites; availability depends on the regulatory status above and on your state.
Disclosure: links marked sponsored below are affiliate links. If you sign up or buy through one we may earn a commission, at no extra cost to you. Commissions do not change what we list, how we rank it, or what the research pages say. How we make money.
Hone Health
Compounds
sermorelin, nad
Pricing
From $175/month. Published on honehealth.com at check time: sermorelin $175/month; other medications listed at $20 to $199/month plus membership. Membership is $25/month (Basic: labs every 6 months, consults purchased separately) or $155/month (Premium: labs, physician consults and medication access); the initial 50+ biomarker test is $65. State coverage is not stated on the pages we read, so it is recorded here as nationwide until confirmed.
From $99/month. Published on livevital.io at check time: $99 to $299 per month depending on the peptide, sold as 10-week courses. GHK-Cu $99/month; BPC-157 and Wolverine $116/month; Glow, Klow and MOTS-c $149/month; tesamorelin $166/month. The 15-minute phone consult is free and HSA/FSA funds are accepted.io.
From $164/month. Published on joinmidi.com at check time: Midi compounded GLP-1 and GLP-1/GIP from $164 per 4-week supply including shipping and supplies; visits are billed to insurance where in-network or $150 to $250 self-pay; brand-name GLP-1s are sent to a pharmacy of choice at the insurance price. A lower-strength weekly plan is advertised from $34 per week for eligible patients. The GLP-1 page notes that compounded products are not available in every state.